Studying Biomarkers in Samples From Patients With Rhabdomyosarcoma
The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2011 by National Cancer Institute (NCI).
Recruitment status was Active, not recruiting
Recruitment status was Active, not recruiting
Sponsor:
Children's Oncology Group
Collaborator:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT01433237
First received: September 9, 2011
Last updated: September 20, 2011
Last verified: September 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research trial studies biomarkers in samples from patients with rhabdomyosarcoma.
| Condition | Intervention |
|---|---|
|
Sarcoma |
Genetic: RNA analysis Genetic: gene expression analysis Other: laboratory biomarker analysis |
| Study Type: | Observational |
| Official Title: | A Retrospective Study on the Diagnostic Value of Serum miR-206 in Rhabdomyosarcoma |
Resource links provided by NLM:
MedlinePlus related topics:
Soft Tissue Sarcoma
Genetic and Rare Diseases Information Center resources:
Malignant Mesenchymal Tumor
Soft Tissue Sarcoma
U.S. FDA Resources
Further study details as provided by National Cancer Institute (NCI):
Primary Outcome Measures:
- Serum miR-206 as a biomaker for RMS [ Designated as safety issue: No ]
| Estimated Enrollment: | 40 |
| Study Start Date: | September 2011 |
| Estimated Primary Completion Date: | December 2011 (Final data collection date for primary outcome measure) |
OBJECTIVES:
- Determine whether circulating muscle-specific microRNAs, especially serum miR-206, are potential biomarkers for rhabdomyosarcoma (RMS).
OUTLINE: Archived serum samples are analyzed for miR-206 expression.
PROJECTED ACCRUAL: A total of 15 samples from patients with alveolar rhabdomyosarcoma (RMS), 15 from patients with embryonal RMS, and 10 from patients without RMS will be accrued for this study.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
DISEASE CHARACTERISTICS:
- Serum specimens of rhabdomyosarcoma (RMS), embryonal RMS, and non-RMS available from the Soft Tissue Sarcoma committee of Children's Oncology Group
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- Not specified
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01433237
Please refer to this study by its ClinicalTrials.gov identifier: NCT01433237
Sponsors and Collaborators
Children's Oncology Group
Investigators
| Principal Investigator: | Hajime Hosoi | Kyoto Prefectural University of Medicine |
More Information
Additional Information:
No publications provided
| Responsible Party: | Peter C. Adamson, Children's Oncology Group - Group Chair Office |
| ClinicalTrials.gov Identifier: | NCT01433237 History of Changes |
| Other Study ID Numbers: | CDR0000710881, COG-ARST12B1 |
| Study First Received: | September 9, 2011 |
| Last Updated: | September 20, 2011 |
| Health Authority: | United States: Federal Government |
Keywords provided by National Cancer Institute (NCI):
|
embryonal childhood rhabdomyosarcoma adult rhabdomyosarcoma alveolar childhood rhabdomyosarcoma adult soft tissue sarcoma childhood rhabdomyosarcoma |
Additional relevant MeSH terms:
|
Rhabdomyosarcoma Myosarcoma Neoplasms Neoplasms by Histologic Type |
Neoplasms, Connective and Soft Tissue Neoplasms, Muscle Tissue Sarcoma |
ClinicalTrials.gov processed this record on February 27, 2015